Pipeline
In-house Pipeline
Pipelines independently developed by Oncocross.
Program
Indication
| Program | Indication | In silico | Preclinical | IND | Cinical Trials |
|---|---|---|---|---|---|
| OC212e | Anti-cancer agent |
OC212e
Anti-cancer agent
|
|||
| OC901 | Neurodegenerative disorders |
OC901
Neurodegenerative disorders
|
|||
Partnered Pipeline
Pipelines being jointly developed with partners.
Program
Indication
| Program | Indication | In silico | Preclinical | IND | Cinical Trials |
|---|---|---|---|---|---|
| DW1023 | Anti-cancer agent |
DW1023
Anti-cancer agent
|
|||